Several pharma/biotech companies collaborate for the development and commercialization of products. These collaborations make sense as they allow the companies to bring together their expertise, technical knowhow and resources. Where financial terms are concerned, these agreements are typically structured to include an upfront payment and additional payments on the achievement of milestones besides royalties.
Earlier this week, Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) announced that it has received a milestone payment of $2 million from partner United Therapeutics Corp. (NASDAQ: UTHR) for the launch of Orenitram (treprostinil) extended-release tablets. Supernus will also receive royalties on net sales of Orenitram and additional payments on the achievement of certain milestones.
We note that Orenitram was developed by United Therapeutics using Supernus' patented technology platform. It was approved in Dec 2013 for the treatment of pulmonary arterial hypertension (PAH) patients (in World Health Organization (WHO) Group I) for improving their exercise capacity. The product was launched in Apr 2014.
We note that subcutaneous and intravenous formulations of Orenitram are already available under the trade name Remodulin for the treatment of PAH.
Orenitram has orphan drug status in the EU for the treatment of PAH. An application for orphan drug designation for Orenitram is under the U.S. Food and Drug Administration's (FDA) review.
The milestone payment of $2 million received by Supernus will add to the company's topline. In 2014, Supernus expects revenues in the range of $75 million−$85 million. The Zacks Consensus Estimate for revenues of $80 million is within this guidance range.
Supernus carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Mallinckrodt plc (NYSE: MNK) and Akorn, Inc. (NASDAQ: AKRX). While Mallinckrodt carries a Zacks Rank #1 (Strong Buy), Akorn holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AKORN INC (NASDAQ: AKRX): Free Stock Analysis Report
MALLINCKRODT PL (NYSE: MNK): Free Stock Analysis Report
SUPERNUS PHARMA (NASDAQ: SUPN): Free Stock Analysis Report
UTD THERAPEUTIC (NASDAQ: UTHR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!